Notably, NIT treatment was initiated 4 wks from the onset of trauma as a delayed intervention
Protein shakes, smoothies, and bone broth provide calories and nutrients when chewing a meal feels impossible
What is included Step-by-step video demonstrations of the treatment you can watch as many times as you like
PMID 3239770
Latin America held a 3% share of the market in 2025 and is expected to grow at a significant CAGR of 14% during the projection period, driven by GLP-1 medications that are driving structural health and economic shifts across Latin America by curbing surging obesity and type-2 diabetes rates, spurring vast biopharma investments, and fundamentally changing consumer habits in the fast-moving consumer goods sector

#ContinuousLearning #Immunology #PharmaInsights #AutoimmuneDisorders #MarketAccess #Biosimilars #PrecisionMedicine #ProfessionalGrowth To view or add a comment, sign in MSDs pipeline in a product approach to tulisokibart continues as it moves the monoclonal antibody into three phase IIb clinical trials for immune-mediated inflammatory diseases To view or add a comment, sign in Eli Lilly and Companys Omvoh Shows 4-Year Sustained Efficacy in Ulcerative Colitis Eli Lilly's ( Omvoh (mirikizumab-mrkz) maintained durable efficacy and safety over four years in patients with moderately to severely active ulcerative colitis